Publication | Closed Access
Development of Highly Potent GAT1 Inhibitors: Synthesis of Nipecotic Acid Derivatives by Suzuki–Miyaura Cross‐Coupling Reactions
34
Citations
33
References
2015
Year
Peptide SciencePharmacotherapyNew SeriesChemical BiologyPharmaceutical ChemistryMolecular PharmacologyMedicinal ChemistrySelective Mgat1 InhibitorsPotent BinderSuzuki–miyaura Cross‐coupling ReactionsBiochemistryMechanism Of ActionNon-peptide LigandPharmacologyMolecular ModelingNatural Product SynthesisBiomolecular EngineeringFunctional SelectivityNatural SciencesRational Drug DesignMedicineNipecotic Acid DerivativesDrug DiscoveryAlpha-adrenergic Pharmacology
A new series of potent and selective mGAT1 inhibitors has been identified, featuring a nipecotic acid residue and an N-butenyl linker with a 2-biphenyl residue at the ω-position. Docking, combined with MD calculations, revealed a binding mode for the new compounds similar to that of tiagabine, the only mGAT1 inhibitor currently approved as antiepileptic drug. For the synthesis, a Suzuki-Miyaura cross-coupling reaction was used as a key step by which variously substituted biaryl subunits were assembled. Biological evaluation revealed several compounds that possess binding affinities and inhibitory potencies toward mGAT1, together with subtype selectivities against mGAT2-mGAT4 that were similar to or even higher than those for tiagabine. A derivative carrying the 2',4'-dichloro-2-biphenyl moiety attached to N-but-3-enylnipecotic acid at the terminal position of the linker chain was found to be the most potent binder, with the racemic form of the compound displaying a binding affinity of 8.05±0.13 (pKi ), while the R enantiomer exhibited an affinity value of 8.33±0.06 (pKi ).
| Year | Citations | |
|---|---|---|
Page 1
Page 1